1. Subjects must have recurrent or persistent platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with measureable disease (as defined by RECIST 1.1.) after first or second line platinum-based chemotherapy, for which treatment with PLD is indicated. Platinum-based therapy is defined as treatment with carboplatin, cisplatin or another organoplatinum compound. Platinum-resistant is defined as having a platinum-free interval (PFI) of < 12 months after first- or second-line platinum-based chemotherapy, or having disease progression while receiving second-line platinum-based chemotherapy. 
Subjects are allowed to have received, but are not required to have received: 
one additional cytotoxic regimen and/or PARP inhibitor for management of recurrent or persistent disease. 
biologic therapy (e.g., bevacizumab) as part of their primary treatment regimen or part of their treatment for management of recurrent or persistent disease. 
2. Histologic documentation of the original primary tumor. 
3. Documented radiographic disease progression < 12 months after the last dose of first- or second-line platinum-based chemotherapy. 
4. Subjects in Phase 2 must have disease amenable to biopsy and must be willing to undergo pre- and post-treatment tumor biopsies. Optional for Phase 1. 
Note: archival tissue will be requested for all subjects preferably from primary tumor site prior to cancer treatment; however, archival tissue is not a requirement for study entry. 
5. ECOG performance status of 0 or 1. 
6. Laboratory parameters for vital functions should be in the normal range. Laboratory abnormalities that are not clinically significant are generally permitted, except for the following laboratory parameters, which must be within the ranges specified, regardless of clinical significance: 
Hemoglobin: ≥ 9 g/dL 
Neutrophil count: ≥ 1.5 x 109/L 
Platelet count: ≥ 100,000/mm3 
Serum creatinine, ≤ 1.5x Institutional Upper Limit of Normal (ULN), or Creatinine Clearance ≥ 50 mL/min (by Cockcroft-Gault formula) 
Serum bilirubin: ≤ 1.2 mg/dL 
AST/ALT: ≤ 2.5 x ULN 
Alkaline phosphatase: ≤ 2.5 x ULN 
7. Age ≥18 years. 
8. Able and willing to give valid written informed consent. 
9. Body weight > 30 kg 

NCT02431559_inc_T7
Measurement
Hemoglobin
NCT02431559_inc_T8
Value
≥ 9 g/dL
NCT02431559_inc_T9
Value
≥ 1.5 x 109/L
NCT02431559_inc_T10
Measurement
Neutrophil count
NCT02431559_inc_T11
Value
≥ 100,000/mm3
NCT02431559_inc_T12
Measurement
Platelet count
NCT02431559_inc_T13
Measurement
Serum creatinine
NCT02431559_inc_T14
Value
≤ 1.5x Institutional Upper Limit of Normal (ULN)
NCT02431559_inc_T15
Measurement
Creatinine Clearance
NCT02431559_inc_T16
Value
≥ 50 mL/min
NCT02431559_inc_T17
Qualifier
Cockcroft-Gault formula
NCT02431559_inc_T18
Measurement
Serum bilirubin
NCT02431559_inc_T19
Value
≤ 1.2 mg/dL
NCT02431559_inc_T20
Condition
primary peritoneal carcinoma
NCT02431559_inc_T21
Condition
carcinoma fallopian tube
NCT02431559_inc_T22
Condition
carcinoma epithelial ovarian
NCT02431559_inc_T23
Qualifier
recurrent
NCT02431559_inc_T24
Qualifier
persistent
NCT02431559_inc_T25
Qualifier
platinum-resistant
NCT02431559_inc_T27
Scope
epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
NCT02431559_inc_T26
Scope
recurrent or persistent
NCT02431559_inc_T28
Condition
measureable disease
NCT02431559_inc_T29
Temporal
after first line platinum-based chemotherapy
NCT02431559_inc_T30
Reference_point
first line platinum-based chemotherapy
NCT02431559_inc_T31
Temporal
after second line platinum-based chemotherapy
NCT02431559_inc_T32
Reference_point
second line platinum-based chemotherapy
NCT02431559_inc_T33
Scope
after first or second line platinum-based chemotherapy
NCT02431559_inc_T34
Procedure
treatment with PLD
NCT02431559_inc_T35
Drug
PLD
NCT02431559_inc_T36
Qualifier
indicated
NCT02431559_inc_T39
Procedure
Platinum-based therapy
NCT02431559_inc_T40
Drug
carboplatin
NCT02431559_inc_T41
Drug
cisplatin
NCT02431559_inc_T42
Drug
another organoplatinum compound
NCT02431559_inc_T44
Scope
carboplatin, cisplatin or another organoplatinum compound
NCT02431559_inc_T45
Measurement
platinum-free interval (PFI)
NCT02431559_inc_T46
Temporal
< 12 months after first- or second-line platinum-based chemotherapy
NCT02431559_inc_T47
Reference_point
first- or second-line platinum-based chemotherapy
NCT02431559_inc_T48
Condition
Platinum-resistant
NCT02431559_inc_T49
Condition
disease progression
NCT02431559_inc_T50
Procedure
second-line platinum-based chemotherapy
NCT02431559_inc_T51
Scope
disease progression while receiving second-line platinum-based chemotherapy
NCT02431559_inc_T52
Scope
platinum-free interval (PFI) of < 12 months after first- or second-line platinum-based chemotherapy, or having disease progression while receiving second-line platinum-based chemotherapy
NCT02431559_inc_T54
Drug
cytotoxic regimen
NCT02431559_inc_T55
Drug
PARP inhibitor
NCT02431559_inc_T56
Multiplier
one additional
NCT02431559_inc_T57
Scope
cytotoxic regimen and/or PARP inhibitor
NCT02431559_inc_T58
Condition
disease
NCT02431559_inc_T59
Temporal
persistent
NCT02431559_inc_T60
Temporal
recurrent
NCT02431559_inc_T61
Scope
recurrent or persistent
NCT02431559_inc_T62
Drug
bevacizumab
NCT02431559_inc_T64
Procedure
biologic therapy
NCT02431559_inc_T65
Procedure
primary treatment regimen
NCT02431559_inc_T66
Temporal
persistent
NCT02431559_inc_T67
Temporal
recurrent
NCT02431559_inc_T68
Scope
recurrent or persistent
NCT02431559_inc_T69
Condition
disease
NCT02431559_inc_T70
Procedure
treatment
NCT02431559_inc_T73
Procedure
Histologic
NCT02431559_inc_T74
Condition
original primary tumor
NCT02431559_inc_T75
Value
documentation
NCT02431559_inc_T76
Procedure
radiographic
NCT02431559_inc_T77
Condition
disease progression
NCT02431559_inc_T78
Temporal
< 12 months after the last dose of first- or second-line platinum-based chemotherapy
NCT02431559_inc_T79
Reference_point
the last dose of first- or second-line platinum-based chemotherapy
NCT02431559_inc_T80
Condition
disease amenable to biopsy
NCT02431559_inc_T87
Measurement
ECOG performance status
NCT02431559_inc_T88
Value
0 or 1
NCT02431559_inc_T89
Measurement
Laboratory parameters for vital functions
NCT02431559_inc_T91
Value
normal range
NCT02431559_inc_T92
Measurement
AST/ALT
NCT02431559_inc_T93
Value
≤ 2.5 x ULN
NCT02431559_inc_T94
Measurement
Alkaline phosphatase
NCT02431559_inc_T95
Value
≤ 2.5 x ULN
NCT02431559_inc_T97
Person
Age
NCT02431559_inc_T98
Value
≥18 years
NCT02431559_inc_T103
Measurement
Body weight
NCT02431559_inc_T104
Value
> 30 kg